icon-folder.gif   Conference Reports for NATAP  
 
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014		 Back grey_arrow_rt.gif
 
 
 
HBV at AASLD
 
 
 
  • Phase 1a Safety and Pharmacokinetics of NVR 3-778, a Potential First-In-Class HBV Core Inhibitor - (01/16/15)
     
  • Curing HBV....attacking cccDNA "Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease" - (01/12/15)
     
  • Phase 1a Safety and Pharmacokinetics of NVR 3-778, a Potential First-In-Class HBV Core Inhibitor - (01/12/15)
     
  • Novira Therapeutics Announces Presentation of Phase 1a - Safety and Pharmacokinetic Data for NVR 3-778 - (01/12/15)
     
  • The Antiviral Response to the Toll-Like Receptor 7 Agonist GS-9620 in Preclinical Models of Chronic Hepatitis B is Associated With an Intrahepatic Cytotoxic T Cell Transcriptional Signature - (01/12/15)
     
  • Cytokines Induced by a Toll-Like Receptor 7 Agonist Potently Inhibit HBV RNA, DNA, and Antigen Levels in Primary Human Hepatocytes - (01/12/15)
     
  • Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in Caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF) - (01/09/15)
     
  • HBsAg Loss With Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a in Chronic Hepatitis B: Results of a Global Randomized Controlled Trial - (01/09/15)
     
  • Long-Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection Is Safe and Well Tolerated and Associated with Durable Virologic Response with No Detectable Resistance: 8 Year Results from Two Phase 3 Trials - (01/09/15)
     
  • No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) in HBeAg+ and HBeAg- Patients With Chronic Hepatitis B (CHB) After Eight Years of Treatment - (01/09/15)
     
  • HBsAg Loss With Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a in Chronic Hepatitis B: Results of a Global Randomized Controlled Trial - (01/09/15)
     
  • Intrahepatic Transcriptional Signature of Exhausted T Cells in Chimpanzees Chronically Infected With HBV - (01/09/15)
     
  • The Antiviral Response to the Toll-Like Receptor 7 Agonist GS-9620 in Preclinical Models of Chronic Hepatitis B Is Associated With an Intrahepatic Cytotoxic T Cell Transcriptional Signature - (01/09/15)
     
  • Cytokines Induced by a Toll-Like Receptor 7 Agonist Potently Inhibit HBV RNA, DNA, and Antigen Levels in Primary Human Hepatocytes - (01/09/15)
     
  • The Safety and Efficacy of Entecavir and Tenofovir Combination Therapy for Chronic Hepatitis B in Patients with Previous Nucleos(t)ide Treatment Failure: Week 96 Results of the ENTEBE study - (01/09/15)
     
  • Entecavir reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B - (01/09/15)
     
  • A Baseline Predictive Tool for Selecting HBeAg-Negative Chronic Hepatitis B Patients Who Have a High Probability of Achieving Sustained Immune Control with Peginterferon Alfa-2a - (01/09/15)
     
  • A Predictive Tool for Selecting HBeAg-Positive Chronic Hepatitis B Patients Who Have a High Probability of HBV DNA Suppression and HBeAg Seroconversion with Peginterferon Alfa-2a - (01/09/15)
     
  • HBeAg Levels Predict HBeAg Seroconversion During the Immune Clearance Phase of Chronic Hepatitis B in Patients Receiving Nucleot(s)ide Analogue Therapy - (01/09/15)
     
  • Loss of Immune Tolerance Is Associated With HBV Genotype-Specific Patterns of Accumulation of Basal Core Promoter and Precore Variants, Leading to Decline in HBeAg and HBsAg Levels - (01/09/15)
     
  • Entecavir Safety & Effectiveness in a National Cohort of Chronic Hepatitis B Patients in the USA - the ENUMERATE Study - (01/07/15)
     
  • Tenofovir Montherapy in Chronic Hepatitis B Patients with Genotypic Resistance to Previous Antiviral Therapy - a Cohort Study - (01/07/15)
     
  • Efficacy of Entecavir plus Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multi-Drug Resistant Strains (2) - (01/07/15)
     
  • Efficacy of Entecavir plus Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multi-Drug Resistant Strains - (01/07/15)
     
  • Entecavir plus adefovir or entecavir plus tenofovir for patients with chronic hepatitis B resistant to neucleot(s)ide analogues - (01/07/15)
     

    		•